K2 Principal Fund’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

K2 Principal Fund’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-30,093	Closed	-$3.96M	–	492
2020 Q4	$3.96M	Buy	+30,093	New	+$2.66M	0.35%	74

K2 Principal Fund's EIDX Position: Q1 2021 in Review

K2 Principal Fund sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 30,093 shares — an estimated $3.96M sold.

K2 Principal Fund first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $3.96M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

K2 Principal Fund reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
K2 Principal Fund sold 30,093 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.96M.
K2 Principal Fund first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
K2 Principal Fund's Eidos Therapeutics, Inc. Common Stock position peaked at $3.96M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on K2 Principal Fund's 13F filing for Q1 2021, filed 14 May 2021.